Serelaxin in HF

AHA: Is Novel HF Drug Too Good to Be True?

By Chris Kaiser, Cardiology Editor, MedPage Today

Published: November 06, 2012

Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco

Click the bottom right corner of the video player for full screen.

LOS ANGELES -- A novel drug for acute heart failure could be a "game-changer," but there are concerns about whether the mortality benefit is real or chance, experts said here.

The RELAX-AHF (RELAXin in Acute Heart Failure) trial -- which is testing serelaxin, a drug that relaxes blood vessels -- met one of its co-primary efficacy endpoints (P=0.007), but missed a second (P=0.70). Both co-primary endpoints dealt with self-reported improvements in dyspnea and well-being./.../